The plants of Cannabis genus are constituted by a diversity of substances, among which the cannabinoids stand out, a group of active compounds which have been widely explored by the medical sciences due to their pharmacological properties. Cannabidiol (CBD) is a cannabinoid without psychotropic effects, besides having good tolerability and low toxicity, even when administered chronically. Among its multiple therapeutic effects, it is notable its anticonvulsant activity, demonstrated in pre-clinical and clinical tests. Epilepsies are severe disorders, leading to several damages to the health and quality of life of those affected. In this sense, antiepileptic drugs (AEDs) are essential to the improvement of the quality of life of these patients, either because they block the seizures or because they, at least, reduce their frequency and/or severity. However, a large proportion of patients with epilepsy are resistant or refractory to conventional AEDs, being, thus, necessary the development and application of new AEDs, as well as of new drug delivery systems that optimize the effects and pharmacokinetic parameters of existing AEDs. In this context, the main goal of this study is to investigate the efficacy of CBD vehiculated in a new nanoemulsion system (CBDne) in the treatment of rats submitted to a model of Status Epilepticus (SE) induced by intra-hippocampal pilocarpine microinjection (Pilo-IH). Therefore, male rats of the Sprague Dawley strain will be submitted to stereotaxic surgery to implant a chemitrode in the left hippocampus and a recording electrode in the contralateral hippocampus. Past the recovery time, these animals will be treated with a single intravenous dose of CBDne or with the empty nanoemulsion (neØ), followed by the microinjection of Pilo-IH, to induce seizures. Recordings of video-EEG will be used to determine the presence of SE, the latency of beginning and severity of seizures. The data will be processed and statistically analyzed, through comparison between the control and treated groups. At the end, we expect that the new delivery system presents advantages in relation to the control of the seizures and neuroprotection. The proposed delivery system might offer new possibilities for the use of CBD in the treatment of the epilepsies.
News published in Agência FAPESP Newsletter about the scholarship: